Skip to main content

Table 3 Progression of vitreous hemorrhage score during the study in Group B

From: Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial

Group B

Baseline

8 Weeks

16 Weeks

24 Weeks

Grade 0

0

31

31

30

Grade 1

1

1

1

1

Grade 2

11

0

0

0

Grade 3

23

3

3

4